These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments.   

investors@repligen.com

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
7/27/2016
7:30 AM ET
Press Release

Repligen to Report Second Quarter 2016 Financial Results

7/27/2016

WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter 2016 financial results on Thursday, August 4, 2016. T...

 Continue Reading
6/2/2016
7:30 AM ET
Press Release

Repligen to Present at Jefferies 2016 Healthcare Conference

6/2/2016

WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs,...

 Continue Reading
5/26/2016
2:52 PM ET
Press Release

Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference

5/26/2016

WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, t...

 Continue Reading
5/19/2016
8:41 AM ET
Press Release

Repligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 2021

5/19/2016

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an underwritten public offering of $100 million aggregate principal...

 Continue Reading
5/18/2016
4:20 PM ET
Press Release

Repligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 2021

5/18/2016

WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 million aggregate principal amount of Convertible Senior Notes d...

 Continue Reading
Displaying 1 to 5 (of 179 releases)